Application of recombinant BMP-7 on persistent upper and lower limb non-unions

Area of Science:

• Orthopedic Surgery
• Regenerative Medicine
• Biomaterials

Background:

• Persistent fracture non-unions present a significant clinical challenge.
• Previous treatments often involve multiple surgeries and autologous bone grafts.
• Novel bone-stimulating agents are needed to improve healing rates.

Purpose of the Study:

• To evaluate the efficacy and safety of recombinant bone morphogenetic protein 7 (rhBMP-7) for treating persistent fracture non-unions.
• To assess rhBMP-7 as a bone-stimulating agent in complex orthopedic cases.
• To determine the union rates and complication profile associated with rhBMP-7 treatment.

Main Methods:

• A prospective study involving 25 patients with 26 fracture non-unions treated with rhBMP-7.
• Inclusion criteria: persistent non-union across various long bones and clavicle.
• Follow-up included clinical assessment and radiological evaluation of bone union.

Main Results:

• Clinical and radiological union achieved in 92.3% (24/26) of cases.
• Mean time to union was 4.2 months (clinical) and 5.6 months (radiological).
• No complications or adverse effects directly attributed to rhBMP-7 were reported.

Conclusions:

• rhBMP-7 is a safe and effective bone-stimulating agent for treating persistent fracture non-unions.
• It represents a powerful adjunct for surgeons managing challenging orthopedic conditions.
• Further consideration of rhBMP-7 in surgical armamentarium is warranted.